I promised to shut up until the New Year, but glancing at the board I see that rumdum is once again saying that NTM is the biggest opportunity for arikace, and Insmed.
Fud responded that the numbers for non cf bronciecstasis with pseudomonas infection were larger.
What some don't realize is that both arikace and tobi have been through phase II trials for non cf bronciecstasis, with the arikace results coming in far better.
In fact: The Tobi phase II
Thirty-one of 37 (84%) patients in each treatment group reported at least one adverse event. Respiratory system adverse events were reported by 26 (70%) TSI patients and by 19 (51%) placebo patients. The incidence of dyspnea, chest pain, and wheezing was significantly greater in the TSI group
Dyspnea, chest pain, and wheezing with Tobi....... arikace produced a slightly higher incidence of dry cough.
One of the pulmonologists who participated in the FDA-sponsored workshop earlier this year mentioned those adverse effects seen in the Tobi study Bo.
And from what was said in that workshop it appears that the data currently available suggest that pulmonary pseudomonas infection is four or five times as prevalent as pulmonary NTM infection.
I'm guessing Budgie doesn't understand that in countries like the US, where TB infection is rare and people with HIV have access to antiretroviral therapy, one would expect a pulmonary NTM infection to be a consequence of another chronic underlying disease. What else would that disease be if not bronchiectasis?
From memory the rate of NTM infection in bronchiectasis was estimated at 7 or 8% - as opposed to around 33% for pseudomonas infection in bronchiectasis.